The uptick in demand for nanotechnology practices that can
solve several genetic-related diseases has increased of late. The multiplex
assays market size is expected to reach USD 3.11 Billion an approximate
CAGR of 6.80% during the forecast period (2022-2030).The market for multiplex
arrays is advancing due to the increased funding and research being diverted to
the market. Increased awareness of the benefits of multiplex assays is fuelling
the growth of the market over the forecast period. The multifactorial nature of
several diseases and pathological conditions such as Alzheimer and cancer are
motivating the development of the market significantly.
Competitive Analysis
The notable contenders shaping the market development over
the forecast period are Illumina Inc, Bio Rad Laboratories Inc, Thermo Fisher
Scientific Inc, Qiagen, Abcam plc, BD, Agilent Technologies, Meso Scale
Diagnostics LLC, Merck Sharp & Dohme Corp, Quanterix, Bio-Techne, Randox
Detailed Regional Analysis
The North America region is accountable for the prime stake
of the market due to robust R&D activities in this region. The US is a
chief country in terms of biopharmaceutical research and development. The
important factors that drive the development of the market in this region are
the rise in-patient population, and the growing detection of Alzheimer disease,
and a substantial rise in research and development activities of the
pharmaceutical companies for the treatment of diseases such as cancer and
Alzheimer. The Asia Pacific is anticipated to record the highest CAGR during
the forecast period. Due to the increasing geriatric population, mounting
prevalence of cataract, and growing prevalence of Alzheimer disease in this
region. The European region is estimated to note a high CAGR during the
forecast period owing to the increasing geriatric population.
Segmental Analysis
The multiplex
assay market Outlook is segmented on the basis of types, application,
products and services, technology, and end-user. By products and services, the
market is segmented into instrument, consumable, and software and services.
Based on types, the market is segmented into nucleic acid, protein, and
cell-based multiplex assay. On the basis of technology, the market is segmented
into fluorescence detection, flow cytometry, luminescence, multiplex real-time
PCR, and other technologies. On the basis of application, the market is
segmented into clinical diagnostic, research and development, and other
diseases. By end user, the market is segmented into hospital and research institutes,
pharmaceutical and biotechnology companies, clinical laboratories, and other
end-users.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked Research
Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and
Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Multiplex Assays Market – Overview
The uptick in demand for nanotechnology practices that can solve several genetic-related diseases has increased of late. The multiplex assays market is expected to reach USD 3.11 Billion an approximate CAGR of 6.80% during the forecast period (2022-2030).The market for multiplex arrays is advancing due to the increased funding and research being diverted to the market. Increased awareness of the benefits of multiplex assays is fuelling the growth of the market over the forecast period. The multifactorial nature of several diseases and pathological conditions such as Alzheimer and cancer are motivating the development of the market significantly.
Segmental Analysis
The multiplex assay market is segmented on the basis of types, application, products and services, technology, and end-user. By products and services, the market is segmented into instrument, consumable, and software and services. Based on types, the market is segmented into nucleic acid, protein, and cell-based multiplex assay. On the basis of technology, the market is segmented into fluorescence detection, flow cytometry, luminescence, multiplex real-time PCR, and other technologies. On the basis of application, the market is segmented into clinical diagnostic, research and development, and other diseases. By end user, the market is segmented into hospital and research institutes, pharmaceutical and biotechnology companies, clinical laboratories, and other end-users.
Competitive Analysis
The notable contenders shaping the market development over the forecast period are Illumina Inc, Bio Rad Laboratories Inc, Thermo Fisher Scientific Inc, Qiagen, Abcam plc, BD, Agilent Technologies, Meso Scale Diagnostics LLC, Merck Sharp & Dohme Corp, Quanterix, Bio-Techne, Randox
Detailed Regional Analysis
The North America region is accountable for the prime stake of the market due to robust R&D activities in this region. The US is a chief country in terms of biopharmaceutical research and development. The important factors that drive the development of the market in this region are the rise in-patient population, and the growing detection of Alzheimer disease, and a substantial rise in research and development activities of the pharmaceutical companies for the treatment of diseases such as cancer and Alzheimer. The Asia Pacific is anticipated to record the highest CAGR during the forecast period. Due to the increasing geriatric population, mounting prevalence of cataract, and growing prevalence of Alzheimer disease in this region. The European region is estimated to note a high CAGR during the forecast period owing to the increasing geriatric population.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.